TOP > 外国特許検索 > ANTI-S100A8/A9 ANTIBODY AND USE THEREOF

ANTI-S100A8/A9 ANTIBODY AND USE THEREOF

外国特許コード F200010011
整理番号 S2018-0580-C0
掲載日 2020年1月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP016100
国際公開番号 WO 2019208290
国際出願日 平成31年4月15日(2019.4.15)
国際公開日 令和元年10月31日(2019.10.31)
優先権データ
  • 特願2018-087576 (2018.4.27) JP
発明の名称 (英語) ANTI-S100A8/A9 ANTIBODY AND USE THEREOF
発明の概要(英語) Provided is a substance capable of effectively inhibiting cancer metastasis or a medicinal composition effectively acting on an inflammatory disease. The medicinal composition, which comprises an antibody having an antigen binding activity to a S100A8/A9 heterodimer or an antibody fragment thereof as an active ingredient, blocks interaction between S100A8/A9 and receptors thereof and thus strongly inhibits cancer metastasis both in vitro and in vivo or ameliorates inflammation. Namely, the anti-S100A8/A9 antibody or an antibody fragment thereof has an effect of blocking the interaction between S100A8/A9 and the receptors thereof and thus can strongly inhibit cancer metastasis or ameliorate inflammation.
従来技術、競合技術の概要(英語) BACKGROUND ART
The transition control of a malignant tumor, cancer to overcome the problem of the core directly but, from the viewpoint of controlling the transfer of the development of therapeutics is still not large.
S100 Species-specific proteins are expressed, EF-hand calcium-binding having one of the 2 protein, 20 up to now been confirmed by the sub-family of the type. S100 Calcium binding protein 1 family S100A8(MRP8,calgranulin A) and one, and usually co S100A9(MRP14,calgranulin B). S100A8/A9 complex during inflammation (Calprotectin), rheumatoid arthritis and the accumulated fluid (RA), cystic fibrosis, Crohn's disease, ulcerative colitis, allergic dermatitis, such as infection of human chronic inflammatory diseases believed to be involved in the development.
S100A8/A9 complex, e.g. a secreted from the lung, cancer of the remote function to attract, the growth of cancer cells and suitable for fixing an immunosuppressive has a function to create the environment of the lung. (Soil signal) emitted from the S100A8/A9 complex organ cancer cell group on the side of the relationship between the S100A8/A9 receptor (Soil sensor), a transition control mechanism is important in cancer, the discovery of the S100A8/A9 receptor has been reported (Non-Patent Document 1-4). S100A8/A9 receptor as a group, (purine encoding) EMMPRIN, NPTN α (neuroplastin-α), such as NPTN β, MCAM(M-cell adhesion molecule), ALCAM is known. These receptors are expressed in the cancer cells, cancer cells of the S100A8/A9 signal are caught and a function to cause the transition.
S100A8/A9 receptors, encoded by inhibiting the binding purine with attention paid to a cancer or chronic inflammation inhibitor report for the screening methods of the metastatic agents (Patent Document 1). In Patent Document 1, encoded the receptor of the purine and particularly S100A9 is shown, as a result of screening, wormwood extract, japanese crested ibis extract, nettle extract the encoded data S100A9 such as to inhibit the binding of the purines disclosed. S100A8/A9 receptors, cell proliferation by inhibiting the binding NPTN attention is paid to the suppression of the report for the screening method (Patent Document 2). Patent Document 2 is, as a result of screening, wormwood extract, licorice extract, ginseng NPTN the like and inhibiting the binding of S100A8 is disclosed. S100 Inhibitor is a compound, cancer, autoimmune diseases, and neurodegenerative diseases such as inflammatory disease is useful for the treatment (Patent Document 3) have been reported. In addition, S100A9 is useful as a biomarker of inflammatory bowel disease have been reported as well (Patent Document 4).
With S100A9 polyclonal antibodies, immunosuppressive state of an organ cancer metastasis may be useful as the destination image (non-patent document 5), in vitro experiments in breast cancer cells and inhibit the migration of a report (Non-Patent Document 6). Further S100A8 polyclonal antibody, a polyclonal antibody is a polyclonal antibody combination of S100A8 S100A9, in in vivo experiments using a mouse from the tail vein of the cancer cells administered to the lungs and to suppress the transition of a report (Non-Patent Document 7). S100 Family is as described above, cancer metastasis and related to, and/or S100A9 and S100A8 binding to a receptor is suppressed, inhibition of cancer and chronic inflammation would inhibit the transfer. However, used in the above non-patent document 5-7 S100A8 S100A9 or a polyclonal antibody is a polyclonal antibody, antigen S100A9 and S100A8 respectively as in the above-mentioned is made, the reactivity of the heterodimer S100A8/A9 (antigen binding activity) and is completely unknown.
Is the non-patent document 8, to prepare a heterodimer S100A8/A9, the disclosure of which is to be purified. Malignant tumors more effectively inhibiting the development of drugs that may be desired.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OKAYAMA UNIVERSITY
  • NIIGATA UNIVERSITY
  • GUNMA UNIVERSITY
  • KAWASAKI GAKUEN EDUCATIONAL FOUNDATION
  • 発明者(英語)
  • SAKAGUCHI, Masakiyo
  • TOYOOKA, Shin-ichi
  • TOMIDA, Shuta
  • SHIEN, Kazuhiko
  • SATO, Hiroki
  • KINOSHITA, Rie
  • FUTAMI Junichiro
  • ARAKI, Kota
  • OKAZAKI, Mikio
  • KONDO, Eisaku
  • INOUE, Yusuke
  • YAMAUCHI, Akira
国際特許分類(IPC)

PAGE TOP

close
close
close
close
close
close